에서 실시간으로 운영 중이에요! 자세히 알아보기

SANUWAVE Health Inc

SNWV

시가총액 US$4267만

4.96 USD

-0.21

4.06%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

-4.06%

5일

-13.59%

1개월

17.54%

3개월

-25.41%

6개월

-72.48%

연초 이후

-82.83%

1년

-85.83%

5년

-82.9%

10년

-82.9%

소개: SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.

직원 수: 55

건강관리 의료기기

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 20%

중립 80%

부정적 0%

SRK Capital 2026 Semi-Annual Portfolio Update

SRK Fund I, LP increased 26.80% during the first half of the year. In contrast, the S&P 500 and the Russell 2000 returned 10.18% and 22.57%, respectively. ImmuCell delivered a strong first quarter in 2026, underscoring the earnings power and cash-flow potential of its core First Defense franchise after the company's strategic exit from Re-Tain. Since divesting its capital-intensive ammunition manufacturing business in April 2025, Outdoor Holding Company has operated as a pure-play, asset-light marketplace through GunBroker.com.

SRK Capital 2026 Semi-Annual Portfolio Update

SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript

Sanuwave Health Q2 Earnings Call Highlights

Sanuwave Health NASDAQ: SNWV reported second-quarter 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier, as lower UltraMIST system sales offset continued growth in the company's recurring applicator business.

Sanuwave Health Q2 Earnings Call Highlights

Sanuwave Announces Q2 FY2026 Financial Results

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.

Sanuwave Announces Q2 FY2026 Financial Results

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results

EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 7, 2026, at 8:30 AM (ET) to present its Q2 2026 financial results.

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results

Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $9.6 to $9.8 million, above the high end of the revised guidance range of $8.5 to $9.5 million provided in the Company's press release dated June 16, 2026.

Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

Sanuwave Health Updates Second Quarter 2026 Guidance

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, below the guidance provided on the Q1 earnings call on May 13 of this year.

Sanuwave Health Updates Second Quarter 2026 Guidance

Sanuwave Health Q1 Earnings Call Highlights

Sanuwave Health NASDAQ: SNWV reported record first-quarter revenue and rising consumables utilization, while management said the advanced wound care market began to recover after a difficult start to the year tied to changes in reimbursement for skin substitutes.

Sanuwave Health Q1 Earnings Call Highlights

SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript

SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript

SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript

Zacks Investment Research

Sanuwave Health Inc. (SNWV) Reports Q1 Loss, Beats Revenue Estimates

Sanuwave Health Inc. (SNWV) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.66 per share a year ago.

Sanuwave Health Inc. (SNWV) Reports Q1 Loss, Beats Revenue Estimates

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.